-
Psychedelics M&A: Beckley Psytech Acquires Eleusis Therapeutics, Strengthening Drug Pipeline And R&D Team
Monday, October 24, 2022 - 3:00pm | 628Private psychedelics medicine company Beckley Psytech Ltd. has acquired 100% of clinical-stage life sciences company Eleusis Therapeutics Ltd., entitling the former to full developmental and commercial rights of the latter’s assets. Eleusis CEO Shlomi Raz will become Beckley’...
-
From Finance To Psychology, Shlomi Raz, CEO Of Eleusis: Meet Our Speakers
Friday, April 8, 2022 - 8:29pm | 581CEO and founder of psychedelics company Eleusis, Shlomi Raz has extensive experience in managing companies. With a BS in Finance and a later an MA in Psychology, Raz became a vice president at JP Morgan (NYSE: JPM) and managing director at Goldman Sachs (NYSE: GS). In 2013, he founded Eleusis...
-
Psychedelics Firm Eleusis Goes Public Via Merger With Silver Spike Acquisition Creating $450M Company
Thursday, January 20, 2022 - 9:26am | 742British psychedelics company Eleusis will go public via a merger with Silver Spike Acquisition Corp. II (“SPKB”) (NASDAQ: SPKB), a special purpose acquisition company sponsored by an affiliate of Silver Spike Capital. The two companies confirmed Thursday they have signed a...